Anne Li August 12th, 2017 email@example.com
Clinicians today have a huge arsenal of drugs at their disposal for treating cancers. But many chemotherapeutic agents pose stubborn challenges: they cause serious side effects, some cancers develop resistance, and many chemotherapies demonstrate low bio-availability. A potential solution lies in the synergistic combination of a chemotherapeutic drug with engineered genetic material. New hybrid materials combine a lipid 'container' for transfection and a protein capsule to deliver a chemical one-two punch.
See original article at: https://www.sciencedaily.com/releases/2017/08/170809140117.htm